Registered title, quoted from ClinicalTrials.gov
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by West China Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07655661, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, including signet ring cell carcinoma, mucinous adenocarcinoma, and hepatoid adenocarcinoma.
Inclusion criterion 1
No prior systemic therapy for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Previous neoadjuvant or adjuvant therapy is allowed if completed at least 6 months before enrollment without evidence of recurrence or progression.
Inclusion criterion 5
Recovery of prior treatment-related toxicities to Grade 0-1 or baseline level.
Inclusion criterion 10
Prior anti-PD-1, anti-PD-L1, anti-CTLA-4, or other immune checkpoint inhibitor therapy.
Exclusion criterion 7
ECOG performance status 0-1.
Inclusion criterion 6
At least one measurable lesion according to RECIST version 1.1.
Inclusion criterion 7
Active hepatitis B, hepatitis C, or HIV infection.
Exclusion criterion 9
Negative pregnancy test for women of childbearing potential and agreement to use effective contraception.
Inclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07655661, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, including signet ring cell carcinoma, mucinous adenocarcinoma, and hepatoid adenocarcinoma.
- Unresectable recurrent or metastatic disease confirmed by imaging and surgical evaluation.
- Age 18 to 75 years.
- Expected survival greater than 3 months.
- No prior systemic therapy for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Previous neoadjuvant or adjuvant therapy is allowed if completed at least 6 months before enrollment without evidence of recurrence or progression.
- ECOG performance status 0-1.
- At least one measurable lesion according to RECIST version 1.1.
- Availability of tumor tissue for PD-L1 testing.
- Adequate hematologic, hepatic, renal, and coagulation function.
- Recovery of prior treatment-related toxicities to Grade 0-1 or baseline level.
- Negative pregnancy test for women of childbearing potential and agreement to use effective contraception.
- Ability to understand and willingness to sign informed consent.
Exclusion Criteria:
- HER2-positive gastric or gastroesophageal junction adenocarcinoma.
- Squamous cell carcinoma, undifferentiated carcinoma, or mixed histology.
- Active or uncontrolled central nervous system metastases.
- Uncontrolled pleural effusion, ascites, or clinically significant pericardial effusion.
- Weight loss greater than 20% within 2 months before enrollment.
- Major surgery within 28 days before enrollment.
- Prior anti-PD-1, anti-PD-L1, anti-CTLA-4, or other immune checkpoint inhibitor therapy.
- Active autoimmune disease requiring systemic treatment.
- Active hepatitis B, hepatitis C, or HIV infection.
- Interstitial lung disease or uncontrolled systemic disease.
- Significant cardiovascular disease within 6 months before enrollment.
- Known hypersensitivity to study drugs or their components.
- Participation in another interventional clinical trial within 4 weeks before enrollment.
- History of substance abuse or severe psychiatric disorder.
- History of rheumatic heart disease or known hypersensitivity to mannatide.
- Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study evaluation.
Quoted from ClinicalTrials.gov, NCT07655661, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07655661, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.